Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 11/2006

01-11-2006 | Review Article

HIV and Aging

Implications for Patient Management

Author: Dr Kelly A. Gebo

Published in: Drugs & Aging | Issue 11/2006

Login to get access

Abstract

Between 2001 and 2004, the percentage of all HIV cases in patients aged ≥50 years increased from 17% to 23%. This concerning increase is expected to continue over the next decade. The increasing prevalence of HIV in these patients is a result of increased longevity in patients treated with highly active antiretroviral therapy (HAART) as well as new primary infections in older patients. While older patients may achieve virological suppression at the same rate as younger patients, the immunological benefit of HAART in older patients may be reduced compared with younger patients. In addition, the toxicities associated with HAART may be worse in older HIV patients, particularly those with underlying renal or hepatic insufficiency. All previous studies evaluating the virological and immunological benefits of HAART in older patients have had relatively small sample sizes and none has compared efficacy or rates of toxicity by HAART treatment class. Co-morbidities are more common in older than in younger patients and can impact on the management of HIV in these patients. Providers must be cognisant of drug-drug interactions and potential adverse effects of HAART regimens when selecting an ideal antiretroviral regimen for older HIV patients. Given the increased longevity and rates of malignancies in HIV-infected patients, providers should also be particularly vigilant in maintaining routine health screening in older HIV patients. Controlled trials on HIV epidemiology, pathogenesis, and therapeutic and clinical outcomes are also needed in older patients. As the HIV-infected population ages, there is a growing need to better determine the effectiveness of HAART in older patients, and to investigate factors associated with a more rapid course of HIV infection in patients aged >50 years.
Literature
1.
2.
3.
Skiest DJ, Rubinstien E, Carley N, et al. The importance of comorbidity in HIV-infected patients over 55: a retrospective case-control study. Am J Med 1996; 101(6): 605–11PubMedCrossRef
4.
Saah AJ, Hoover DR, He Y, et al. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994; 7(3): 287–95PubMed
5.
Ferro S, Salit IE. HIV infection in patients over 55 years of age. J Acquir Immune Defic Syndr 1992; 5(4): 348–53PubMed
6.
Operskalski EA, Stram DO, Lee H, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis 1995; 172(3): 648–55PubMedCrossRef
7.
Phillips AN, Lee CA, Elford J, et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr 1991; 4(10): 970–5PubMed
8.
Blaxhult A, Granath F, Lidman K, et al. The influence of age on the latency period to AIDS in people infected by HIV through blood transfusion. AIDS 1990; 4(2): 125–9PubMedCrossRef
9.
Sutin DG, Rose DN, Mulvihill M, et al. Survival of elderly patients with transfusion-related acquired immunodeficiency syndrome. J Am Geriatr Soc 1993; 41(3): 214–6PubMed
10.
Rothenberg R, Woelfel M, Stoneburner R, et al. Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. N Engl J Med 1987; 317(21): 1297–302PubMedCrossRef
11.
Gaeta TJ, LaPolla C, Melendez E. AIDS in the elderly: New York City vital statistics. J Emerg Med 1996; 14(1): 19–23PubMedCrossRef
12.
Gordon SM, Thompson S. The changing epidemiology of human immunodeficiency virus infection in older persons. J Am Geriatr Soc 1995; 43(1): 7–9PubMed
13.
Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA 1990; 263(3): 402–6PubMedCrossRef
14.
Rosenberg PS, Goedert JJ, Biggar RJ. Effect of age at seroconversion on the natural AIDS incubation distribution. Multicenter Hemophilia Cohort Study and the International Registry of Seroconverters. AIDS 1994; 8(6): 803–10PubMedCrossRef
15.
Stehr-Green JK, Holman RC, Mahoney MA. Survival analysis of hemophilia-associated AIDS cases in the US. Am J Public Health 1989; 79(7): 832–5PubMedCrossRef
16.
Balslev U, Monforte AD, Stergiou G, et al. Influence of age on rates of new AIDS-defining diseases and survival in 6546 AIDS patients. Scand J Infect Dis 1997; 29(4): 337–43PubMedCrossRef
17.
Anastos K, Barron Y, Cohen MH, et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140(4): 256–64PubMed
18.
Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360(9327): 119–29PubMedCrossRef
19.
Collaborative Group on AIDS. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355(9210): 1131–7CrossRef
20.
Darby SC, Ewart DW, Giangrande PL, et al. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors’ Organisation. Lancet 1996; 347(9015): 1573–9PubMed
21.
Longini IM, Clark WS, Gardner LI, et al. The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach. J Acquir Immune Defic Syndr 1991; 4(11): 1141–7PubMed
22.
Hessol NA, Koblin BA, van Griensven GJ, et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978–1991. Am J Epidemiol 1994; 139(11): 1077–87PubMed
23.
Veugelers PJ, Page KA, Tindall B, et al. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol 1994; 140(8): 747–58PubMed
24.
Mauss S. HIV-associated lipodystrophy syndrome. AIDS 2000; 14Suppl. 3: S197–207PubMed
25.
Manfredi R, Calza L, Chiodo F. Gynecomastia associated with highly active antiretroviral therapy. Ann Pharmacother 2001; 35(4): 438–9PubMedCrossRef
26.
Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354(9184): 1112–5PubMedCrossRef
27.
Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12(7): F51–8PubMedCrossRef
28.
Christeff N, Melchior JC, de Truchis P, et al. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999; 13(16): 2251–60PubMedCrossRef
29.
Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 2000; 25Suppl. 1: S4–11PubMed
30.
Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32(1): 130–9PubMedCrossRef
31.
Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14(1): 37–49PubMedCrossRef
32.
Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100(7): 700–5PubMedCrossRef
33.
Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353(9170): 2093–9PubMedCrossRef
34.
Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351(9120): 1959PubMedCrossRef
35.
Moore RD, Keruly JC, Lucas GM. Increasing incidence of cardiovascular disease in HIV-infected persons in care [abstract]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb; Boston (MA)
36.
The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349(21): 1993–2003CrossRef
37.
Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17(17): 2479–86PubMedCrossRef
38.
Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360(9347): 1747–8PubMedCrossRef
39.
Holmberg SD, Moorman AC, Greenberg AE, et al. Trends in rates of myocardial infarction among patients with HIV. N Engl J Med 2004; 350(7): 730–2PubMedCrossRef
40.
Klein D, Hurley LB, Quesenberry CP, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30(5): 471–7PubMedCrossRef
41.
Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37(3): e41–3PubMedCrossRef
42.
Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42(2): 283–90PubMedCrossRef
43.
Lee JC, Marosok RD. Acute tubular necrosis in a patient receiving tenofovir. AIDS 2003; 17(17): 2543–4PubMedCrossRef
44.
Dieleman JP, van Rossum AM, Stricker BC, et al. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defic Syndr 2003; 32(2): 135–42PubMedCrossRef
45.
Kopp JB, Falloon J, Filie A, et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002; 34(8): 1122–8PubMedCrossRef
46.
Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40(8): 1194–8PubMedCrossRef
47.
Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18(17): 2277–84PubMedCrossRef
48.
Dutta SK, Ting CD, Lai LL. Study of prevalence, severity, and etiological factors associated with acute pancreatitis in patients infected with human immunodeficiency virus. Am J Gastroenterol 1997; 92(11): 2044–8PubMed
49.
Reisler RB, Murphy RL, Redfield RR, et al. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr 2005; 39(2): 159–66PubMed
50.
Chehter EZ, Longo MA, Laudanna AA, et al. Involvement of the pancreas in AIDS: a prospective study of 109 postmortems. AIDS 2000; 14(13): 1879–86PubMedCrossRef
51.
52.
Kiser J, Carten M, Wolfe P, et al. Effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. In: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver (CO)
53.
Ship JA, Wolff A, Selik RM. Epidemiology of acquired immune deficiency syndrome in persons aged 50 years or older. J Acquir Immune Defic Syndr 1991; 4(1): 84–8PubMedCrossRef
54.
Centers for Disease Control and Prevention. AIDS among persons aged > or = 50 years: United States, 1991–1996. MMWR Morb Mortal Wkly Rep 1998; 47(2): 21–7
55.
Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother 2006; 57(1): 4–7PubMedCrossRef
56.
57.
Casau NC. Perspective on HIV infection and aging: emerging research on the horizon. Clin Infect Dis 2005; 41(6): 855–63PubMedCrossRef
58.
Manfredi R. HIV disease and advanced age: an increasing therapeutic challenge. Drugs Aging 2002; 19(9): 647–69PubMedCrossRef
59.
Manfredi R. HIV infection and advanced age: emerging epidemiological, clinical, and management issues. Ageing Res Rev 2004; 3(1): 31–54PubMedCrossRef
60.
Cloud GC, Browne R, Salooja N, et al. Newly diagnosed HIV infection in an octogenarian: the elderly are not ‘immune’. Age Ageing 2003; 32(3): 353–4PubMedCrossRef
61.
Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17): 1–19
62.
Mack KA, Ory MG. AIDS and older Americans at the end of the twentieth century. J Acquir Immune Defic Syndr 2003; 33Suppl. 2: S68–75PubMedCrossRef
63.
Crystal S, Akincigil A, Sambamoorthi U, et al. The diverse older HIV-positive population: a national profile of economic circumstances, social support, and quality of life. J Acquir Immune Defic Syndr 2003; 33Suppl. 2: S76–83PubMedCrossRef
64.
Keitz SA, Bastian LA, Bennett CL, et al. AIDS-related Pneumocystis carinii pneumonia in older patients. J Gen Intern Med 1996; 11(10): 591–6PubMedCrossRef
65.
El Sadr W, Gettler J. Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med 1995; 155(2): 184–6PubMedCrossRef
66.
Stall R, Catania J. AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med 1994; 154(1): 57–63PubMedCrossRef
67.
Horner RD, Bennett CL, Rodriguez D, et al. Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995; 152(5): 1435–42PubMed
68.
Butt AA, Dascomb KK, DeSalvo KB, et al. Human immunodeficiency virus infection in elderly patients. South Med J 2001; 94(4): 397–400PubMed
69.
70.
Winningham A, Corwin S, Moore C, et al. The changing age of HIV: sexual risk among older African American women living in rural communities. Prev Med 2004; 39(4): 809–14PubMedCrossRef
71.
Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995; 333(12): 751–6PubMedCrossRef
72.
Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005; 40(5): 609–16PubMedCrossRef
73.
Reiter GS. Comprehensive clinical care: managing HIV as a chronic illness. AIDS Clin Care 2000; 12(2): 13–9PubMed
74.
Betz M, Gebo KA, Barber E, et al. Patterns of diagnoses in hospital admissions in a multi-state cohort of HIV+ adults in 2001. Med Care 2005; 43(9 Suppl.): III13–4
75.
Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 10 1995 Dec; 193 Pt 1: 1–260PubMed
76.
Engels EA. Human immunodeficiency virus infection, aging, and cancer. J Clin Epidemiol 2001; 54 (12 Suppl. 1): S29–34PubMedCrossRef
77.
Bastian L, Bennett CL, Adams J, et al. Differences between men and women with HIV-related Pneumocystis carinii pneumonia: experience from 3,070 cases in New York City in 1987. J Acquir Immune Defic Syndr 1993; 6(6): 617–23PubMed
78.
Sorkin JD, Bolton PA, Greenblatt J, et al. Age, gender, and other predictors of the wasting syndrome among HIV-1-infected injecting drug users. Epidemiology 1995; 6(2): 172–7PubMedCrossRef
79.
Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396(6712): 690–5PubMedCrossRef
80.
Haynes BF, Markert ML, Sempowski GD, et al. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000; 18: 529–60PubMedCrossRef
81.
82.
Zhang L, Lewin SR, Markowitz M, et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999; 190(5): 725–32PubMedCrossRef
83.
Jamieson BD, Douek DC, Killian S, et al. Generation of functional thymocytes in the human adult. Immunity 1999; 10(5): 569–75PubMedCrossRef
84.
Manfredi R, Chiodo F. A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS 2000; 14(10): 1475–7PubMedCrossRef
85.
Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183(8): 1290–4PubMedCrossRef
86.
Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15(6): 735–46PubMedCrossRef
87.
Gebo KA, Moore RD. Treatment of HIV infection in the older patient. Expert Rev Anti Infect Ther 2004; 2(5): 733–43PubMedCrossRef
88.
Knobel H, Guelar A, Valldecillo G, et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS 2001; 15(12): 1591–3PubMedCrossRef
89.
Manfredi R, Calza L, Cocchi D, et al. Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr 2003; 33(1): 112–4PubMedCrossRef
90.
Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003 Jan 15; 36(2): 212–8PubMedCrossRef
91.
Tumbarello M, Rabagliati R, Gaetano Donati K, et al. Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS 2003; 17(1): 128–31PubMedCrossRef
92.
Goodkin K, Shapshak P, Asthana D, et al. Older age and plasma viral load in HIV-1 infection. AIDS 2004; 18Suppl. 1: S87–98PubMed
93.
Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age: results from the French Hospital Database on HIV. AIDS 2004; 18(15): 2029–38PubMedCrossRef
94.
Tumbarello M, Rabagliati R, Gaetano Donati K, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active anti retroviral therapy. BMC Infect Dis 2004; 4(1): 46PubMedCrossRef
95.
Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41(3): 361–72PubMedCrossRef
96.
Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15(14): 1749–56PubMedCrossRef
97.
Grimes RM, Otiniano ME, Rodriguez B, et al. Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis 2002; 34(11): 1530–3PubMedCrossRef
98.
Fleishman JA, Gebo KA, Moore RD. Disparities in virologic suppression among patients with HIV infection. In: Abstracts of the Academy Health Annual Research Meeting; 2004 Jun 6–8; San Diego (CA)
99.
Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15(10): 1261–8PubMedCrossRef
100.
Sauvageone-Matre H, Bannie F, Tabah I, et al. Pharmacokinetics of zidovudine in AIDS patients: influence of age and hepatic disorders [abstract no. MBP 323]. In: Program and abstracts of the 5th International Conference on AIDS (Montreal) Ottawa: International Development Research Centre, 1989
101.
Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61(3): 331–9PubMedCrossRef
102.
103.
Jain RG, Furfine ES, Pedneault L, et al. Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001; 51(3): 151–77PubMedCrossRef
104.
Galli M, Ridolfo A, Gervasoni C. Cardiovascular disease risk factors in HIV-infected patients in the HAART era. Ann N Y Acad Sci 2001; 946(1): 200–13PubMedCrossRef
105.
Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189(6): 1056–74PubMedCrossRef
106.
Van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15(18): 2407–14PubMedCrossRef
107.
Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003; 23(2): 183–94PubMedCrossRef
108.
Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clin Liver Dis 2003; 7(2): 475–99PubMedCrossRef
109.
Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis 2003; 23(2): 167–72PubMedCrossRef
110.
Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003; 23(2): 173–82PubMedCrossRef
111.
Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999 Oct 22; 13(15): F101–7PubMedCrossRef
112.
Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000 Aug; 50(2): 99–107PubMedCrossRef
113.
Bowman L, Carlstedt BC, Hancock EF, et al. Adverse drug reaction (ADR) occurrence and evaluation in elderly inpatients. Pharmacoepidemiol Drug Saf 1996; 5(1): 9–18PubMedCrossRef
114.
Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003; 20(10): 769–76PubMedCrossRef
115.
Shah SS, McGowan JP, Smith C, et al. Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis 2002; 35(10): 1238–43PubMedCrossRef
116.
Nokes K, Holzerner W, Corless I, et al. Health-related quality of life in persons younger and older than 50 who are living with HIV/AIDS. Res Aging 2000; 22(3): 290–310CrossRef
117.
Rabkin JG, McElhiney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS 2004; 18Suppl. 1: S43–8PubMed
118.
Goodkin K, Wilkie FL, Concha M, et al. Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. J Clin Epidemiol 2001; 54Suppl. 1: S35–43PubMedCrossRef
119.
Hinkin CH, Castellon SA, Atkinson JH, et al. Neuropsychiatric aspects of HIV infection among older adults. J Clin Epidemiol 2001; 54Suppl. 1: S44–52PubMedCrossRef
120.
Kilbourne AM, Justice AC, Rabeneck L, et al. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001; 54Suppl. 1: S22–8PubMedCrossRef
121.
Adeyemi OM, Badri SM, Max B, et al. HIV infection in older patients [letter]. Clin Infect Dis 2003; 36(10): 1347PubMedCrossRef
122.
Justice AC, McGinnis KA, Atkinson JH, et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 2004; 18Suppl. 1: S49–59PubMed
123.
Butt AA, Fultz SL, Kwoh CK, et al. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 2004; 40(1): 115–9PubMedCrossRef
124.
Glesby MJ, Hoover DR, Tan T, et al. Herpes zoster in women with and at risk for HIV: data from the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 37(5): 1604–9PubMedCrossRef
125.
Pitts M, Grierson J, Misson S. Growing older with HIV: a study of health, social and economic circumstances for people living with HIV in Australia over the age of 50 years. AIDS Patient Care STDs 2005; 19(7): 460–5PubMedCrossRef
126.
Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285(13): 1736–45PubMedCrossRef
127.
Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21(18): 3447–53PubMedCrossRef
128.
Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97(6): 425–32PubMedCrossRef
129.
Hessol NA, Seaberg E, Preston-Martin S, et al. Cancer risk among participants in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 36(4): 978–85PubMedCrossRef
130.
Biggar RJ, Kirby KA, Atkinson JH, et al. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004; 36: 861–8PubMedCrossRef
131.
Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24(9): 1383–8PubMedCrossRef
132.
Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003; 34(2): 165–73PubMedCrossRef
133.
Soriano V, Garcia-Samaniego J, Valencia E, et al. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15(1): 1–4PubMedCrossRef
134.
Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38Suppl. 2: S90–7PubMedCrossRef
135.
NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19(3): 1–46
136.
de Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003; 2(1): 5–11PubMed
137.
Backus L, Phillips B, Boothroyd D, et al. Hepatitis C coinfection increases mortality in HIV-infected U.S. veterans treated with highly active antiretroviral therapy. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco (CA)
138.
Rimland D, Guest J. Mortality in the HIV Atlanta VA Cohort Study: a 22-year analysis. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco (CA)
139.
Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 2001; 56(2): 257–60PubMedCrossRef
140.
Maschke M, Kastrup O, Esser S, et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000; 69(3): 376–80PubMedCrossRef
141.
Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort. Neurology 2004; 63(5): 822–7PubMedCrossRef
142.
Green DA, Masliah E, Vinters HV, et al. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 2005; 19(4): 407–11PubMedCrossRef
143.
Achim C, Masliah E, Vinters H, et al. Beta-amyloid in the HIV brain. Washington, DC: Society of Neuroscience, 2004
144.
Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004; 18Suppl. 1: S75–8PubMed
145.
Vargas D, Nascimbene C, Lee A, et al. Chemokine and cytokine profiling by protein array technology shows the basal ganglia as the most affected area in HIV dementia [abstract]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)
146.
Berger JR, Arendt G. HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 2000; 14(3): 214–21PubMedCrossRef
147.
Schoenbaum EE, Hartel D, Lo Y, et al. HIV Infection, drug use, and onset of natural menopause. Clin Infect Dis 2005; 41(10): 1517–24PubMedCrossRef
148.
Clark RA, Cohn SE, Jarek C, et al. Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic Syndr 2000; 23(1): 99–100PubMed
149.
Whelan EA, Sandier DP, McConnaughey DR, et al. Menstrual and reproductive characteristics and age at natural menopause. Am J Epidemiol 1990; 131(4): 625–32PubMed
150.
Brambilla DJ, McKinlay SM. A prospective study of factors affecting age at menopause. J Clin Epidemiol 1989; 42(11): 1031–9PubMedCrossRef
151.
Clark RA, Bessinger R. Clinical manifestations and predictors of survival in older women infected with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15(5): 341–5PubMedCrossRef
152.
Klein RS, Lo Y, Santoro N, et al. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis 2005; 41(12): 1794–803PubMedCrossRef
153.
Smith Jr SC, Jackson R, Pearson TA, et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation 2004; 109(25): 3112–21PubMedCrossRef
154.
Jutte A, Schwenk A, Franzen C, et al. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS 1999; 13(13): 1796–7PubMedCrossRef
155.
Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000; 5(8): 329–33PubMed
156.
Cole JW, Pinto AN, Hebel JR, et al. Acquired immunodeficiency syndrome and the risk of stroke. Stroke 2004; 35(1): 51–6PubMedCrossRef
157.
The Writing Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18(13): 1811–7CrossRef
158.
Vittecoq D, Escaut L, Chironi G, et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003; 17Suppl. 1: S70–6PubMedCrossRef
159.
Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33(4): 506–12PubMedCrossRef
160.
Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003; 19(6): 449–55PubMedCrossRef
161.
Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348(8): 702–10PubMedCrossRef
162.
Palacios R, Santos J, Garcia A, et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients: a prospective study in a cohort of naive patients. HIV Med 2006; 7(1): 10–5PubMedCrossRef
163.
Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294(6): 716–24PubMedCrossRef
164.
Pignone M, Rich M, Teutsch SM, et al. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 137(2): 132–41PubMed
165.
Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2005. CA Cancer J Clin 2005; 55(1): 31–44PubMedCrossRef
166.
Reinhold JP, Moon M, Tenner CT, et al. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol 2005; 100(8): 1805–12PubMedCrossRef
167.
Sheth A, Moore RD, Gebo KA. Provision of HIV and routine health maintenance in an urban HIV cohort. AIDS Patient Care STDs 2006; 20(5): 318–25PubMedCrossRef
168.
Holtzman D, Powell-Griner E, Bolen JC, et al. State- and sex-specific prevalence of selected characteristics: behavioral risk factor surveillance system, 1996 and 1997. MMWR CDC Surveill Summ 2000; 49(6): 1–39
169.
Breen N, Wagener DK, Brown ML, et al. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst 2001; 93(22): 1704–13PubMedCrossRef
Metadata
Title
HIV and Aging
Implications for Patient Management
Author
Dr Kelly A. Gebo
Publication date
01-11-2006
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2006
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200623110-00005

Other articles of this Issue 11/2006

Drugs & Aging 11/2006 Go to the issue

Review Article

Risperidone for the Treatment of Neuropsychiatric Features in Dementia

Original Research Article

Potentially Inappropriate Medication Prescribing for Elderly Outpatients in Emilia Romagna, Italy

Therapy in Practice

Prescribing Antiepileptics for the Elderly

Leading Article

Anti-Tumour Necrosis Factor-α Therapy for Rheumatoid and Other Inflammatory Arthropathies

From the World Literature

Gerontology Forum

Review Article

Divalproex Sodium for the Treatment of Behavioural Problems Associated With Dementia in the Elderly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits